News stories about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the specialty pharmaceutical company an impact score of 46.810851870953 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
Several equities research analysts have recently issued reports on SUPN shares. Berenberg Bank started coverage on shares of Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 price objective for the company. BidaskClub cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 26th. B. Riley reaffirmed a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, January 18th. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, January 10th. Finally, ValuEngine raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $51.36.
Shares of SUPN opened at $48.50 on Friday. Supernus Pharmaceuticals has a 1-year low of $29.95 and a 1-year high of $50.04. The firm has a market capitalization of $2,476.36, a P/E ratio of 38.49 and a beta of 1.11.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.18. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The firm had revenue of $88.44 million during the quarter, compared to analysts’ expectations of $87.84 million. equities analysts predict that Supernus Pharmaceuticals will post 1.85 EPS for the current year.
In related news, VP Padmanabh P. Bhatt sold 20,000 shares of the business’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now directly owns 32,500 shares of the company’s stock, valued at $1,561,300. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Victor Vaughn sold 17,850 shares of the business’s stock in a transaction on Thursday, April 19th. The shares were sold at an average price of $47.93, for a total transaction of $855,550.50. Following the completion of the sale, the vice president now directly owns 15,594 shares of the company’s stock, valued at $747,420.42. The disclosure for this sale can be found here. Over the last three months, insiders sold 97,850 shares of company stock valued at $4,536,151. 6.70% of the stock is owned by corporate insiders.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Supernus Pharmaceuticals (SUPN) Stock Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/21/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-supernus-pharmaceuticals-supn-stock-price.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.